CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Teriparatidedrug
Likely dose
Teriparatide 20 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01105832
NCT01105832Phase 4Completed
CompareCT.gov

Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer?

University Hospital, Linkoeping·interventional·Posted Apr 19, 2010·Updated Dec 10, 2014

In Brief

A Phase 4 clinical trial evaluating Teriparatide for Humeral Fracture. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

40 postmenopausal women, with a non-operated proximal humeral fracture, will be randomized to standard treatment (physiotherapy) or standard treatment + Forsteo (rhPTH 1-34) during 4 weeks. Follow-up will be at 7 weeks and 3 months including x-ray and DASH score (The Disabilities of the Arm, Shoulder and Hand) measuring physical function, and pain on a visual analoge scale (VAS). Two doctors, blinded to the treatment, will judge the callus formation and healing on the x-rays and guess the treatment. The DASH score and the pain score will be compared between the treatment groups. The investigators hypotheses are that callus formation and healing will be more pronounced and that patients have less pain and better function in the rhPTH 1-34 group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHumeral Fracture
CountriesSweden
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2010
Enrollment StartApr 1, 2010
Primary CompletionFeb 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.2 years ago

Interventions

Teriparatidedrug

Teriparatide (Forsteo) 20 micrograms daily during four weeks